Premium
Evaluation of the effects of type II radical hysterectomy in the treatment of 960 patients with stage IB–IIB cervical carcinoma: A retrospective study
Author(s) -
Zheng Min,
Huang Long,
He Li,
Ding Hui,
Wang HuiYun,
Zheng LiMin
Publication year - 2010
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21800
Subject(s) - medicine , cervical carcinoma , stage (stratigraphy) , radical hysterectomy , hysterectomy , retrospective cohort study , carcinoma , cervical cancer , gynecology , oncology , surgery , urology , general surgery , cancer , paleontology , biology
Background and Objectives This retrospective study evaluated the feasibility and effectiveness of type II radical hysterectomies alone, or in combination with adjuvant treatment, for the treatment of patients with stage IB–IIB cervical cancer with or without high‐risk factors. Methods A total of 960 stage IB–IIB patients who underwent type II radical hysterectomies between 1995 and 2004 were enrolled and retrospectively analyzed. Results Uterine corpus invasion, parametrial margin involvement, and pelvic lymph node metastasis were identified as independent prognostic factors for stage IB patients. For stage IIA–IIB patients, histologic type, parametrial margin involvement, and pelvic lymph node metastasis were identified as independent prognostic factors. The 5‐year overall survival (OS) rates for patients with stage IB versus stage IIA–IIB cervical carcinomas were 88.4% and 78.5%, respectively. Moreover, adjuvant radiotherapy and chemotherapy improved the 5‐year OS rates of stage IIA–IIB patients associated with high‐risk factors. The overall recurrence rate for this cohort was 14.4%. Conclusions Our findings show that type II radical hysterectomy is a feasible treatment option for stage IB–IIB cervical carcinoma patients. Furthermore, type II radical hysterectomy combined with adjuvant post‐operative therapy improves the OS of women with high‐risk factors for cervical carcinoma. J. Surg. Oncol. 2011; 103:435–441. © 2010 Wiley‐Liss, Inc.